The Cascading Perception of Diverse Anavex Solutions
Ponder the potential public perceptions of three positive Anavex clinical trial results, likely to appear within a year or two.
First, the new trial with 300 Australians with Anavex-favorable Alzheimer’s genes taking Anavex 2-73. I contend it won’t take the entire 48 weeks of that trial for the public to learn of the drug’s efficacy. Last time, word got out that a few Alzheimer’s patients resumed playing the piano well, painted pictures again, etc. That was in a trial with only 32 random, un-selected folks. How Anavex or Australian medical people will keep positive results hidden for the entire 48 months will be interesting. Doubt that it can be done.
Then, perhaps even before the 48 weeks of the Alzheimer’s trial is completed, some mothers with Rett Syndrome little girls (disease happens only in females) may begin to exclaim how their children are sleeping normally, have reduced fits and increased, normalized motor control. That will make front page news stories with about the third mother telling about the successes of her little girl taking “that new, wonderful drug.”
Then, from across the pond, reports begin to appear that Anavex 2-73 is bringing symptomatic relief to Europeans with Parkinson’s.
At that point, the contentions that I and a few others have made — who understand the biochemistry of the Anavex sigma-1 receptor agonist and it’s ability to restore normalized neuron functions, applicable to a diversity of central nervous system diseases — will be then regarded not as hypothetical or dreamy; rather, as real and applicable. Imagine for yourself the news articles that will begin to appear on the topic. Imagine the article titles. (You can do that yourself.)
At its start, Had some retired high school biology teacher claimed that Alexander Fleming’s work with a culture-contaminating mold would eventually result in a totally new class of antibiotic therapies, which would save millions upon millions of lives, that bloke would have been about as highly regarded as a more contemporary retired biology teacher (me) who has proclaimed that Anavex sigma-1 receptor agonists will decidedly change 21st century medicine.
It took a decade of work, and the onset of a world war to get Fleming’s work into commercial production of millions of doses of penicillin. Anavex needs neither. Just the results from one or two of the upcoming clinical trials. Everything will be different and fall into place, then.
Will be fun to watch.
News 
Market Data 
Discover 
